Intensive antithrombotic therapy is necessary for long-term treatment in patients with symptomatic peripheral artery disease after acute myocardial infarction

Abstract Patients with acute myocardial infarction (AMI) who have concomitant peripheral artery disease (PAD) represent a subgroup at high risk of subsequent ischaemic events. This post hoc analysis of PRAGUE-18, a multicenter, randomised trial comparing prasugrel versus ticagrelor in primary PCI, a...

Description complète

Détails bibliographiques

Auteurs principaux:	Jan Matejka, Zuzana Motovska, Ota Hlinomaz, Petr Kala, Milan Hromadka, Ivo Varvarovsky, Jaroslav Dusek, Jiri Jarkovsky, Richard Rokyta, Jan Mrozek, Pavel Cervinka, Stanislav Simek, Jiri Ostransky
Format:	Artigo
Langue:	Inglês
Publié:	Nature Portfolio 2025-11-01
Collection:	Scientific Reports
Sujets:	Acute myocardial infarction Peripheral artery disease Antiplatelet therapy Ticagrelor Prasugrel
Accès en ligne:	https://doi.org/10.1038/s41598-025-24372-2
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!